Phase II Non-Randomized Study Combining Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With High-Dose Chemotherapy Prior to Autologous Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma
Relapse rates after chemotherapy for relapsed, refractory or transformed Non-Hodgkin's
lymphoma (NHL)remain very high. NHL is a radiosensitive tumor. We hypothesize that
targeted radioimmunotherapy combined with high-dose chemotherapy may increase response and
survival rates in a safe and reliable manner.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate
Ahmed Galal, MD
Principal Investigator
McGill University Health Center, Royal Victoria Hospital
Canada: Health Canada
BMA-05-017-ZEV
NCT00438581
March 2007
Name | Location |
---|